GNCA News and Press, Genocea Biosciences Inc. From 11/06/20

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor call with a live Q&A on Monday, November 9 th at 8:30 a.m. EST to provide a...

Genocea Biosciences, Inc. (GNCA) Q3 2020 Earnings Conference Call October 29, 2020 08:30 am ET Company Participants Dan Ferry - Investor Relations, LifeSci Advisors Chip Clark - President and Chief Executive Officer Diantha Duvall - Chief Financial Officer Tom Davis - Chief Medical Officer Je...

Genocea Biosciences (GNCA): Q3 GAAP EPS of -$0.26 misses by $0.02.Revenue of $0.45MPress Release For further details see: Genocea Biosciences EPS misses by $0.02

Initiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy Closed financing with net proceeds of $74.5 million Upcoming pr...

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio we...

Will showcase clinical and immune response s from the ongoing GEN-009 Phase 1/2a trial Will provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the limitations of TIL and TCR therapies Will share new i...

A newly released report titled "Immunotherapy Drugs Market by Type, Therapy Area, End User - Global Forecast to 2025" forecasts the global immunotherapy drugs market to reach USD 274. 6 billion by 2025 from USD 163. 0 billion in 2020, at a CAGR of 11. 0 % during the forecast period. Com...

Genocea Biosciences' (GNCA) +11% in premarket in reaction to the FDA acceptance of investigational new drug application ((IND)) for GEN-011, an adoptive T cell therapy targeting neoantigens.The IND allows to commence a Phase 1/2a trial for GEN-011, in patients who hav...

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s...